Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023)

Inmune Bio's Total Non-Current Liabilities history spans 3 years, with the latest figure at $17.2 million for Q3 2023.

  • For Q3 2023, Total Non-Current Liabilities changed N/A year-over-year to $17.2 million; the TTM value through Sep 2023 reached $17.2 million, changed N/A, while the annual FY2022 figure was $21.1 million, 7.21% up from the prior year.
  • Total Non-Current Liabilities for Q3 2023 was $17.2 million at Inmune Bio, down from $21.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $21.1 million in Q4 2022 and bottomed at $17.2 million in Q3 2023.
  • The 3-year median for Total Non-Current Liabilities is $18.9 million (2021), against an average of $18.9 million.
  • The largest YoY upside for Total Non-Current Liabilities was 7.21% in 2022 against a maximum downside of 7.21% in 2022.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $19.7 million in 2021, then increased by 7.21% to $21.1 million in 2022, then decreased by 18.82% to $17.2 million in 2023.
  • Per Business Quant, the three most recent readings for INMB's Total Non-Current Liabilities are $17.2 million (Q3 2023), $21.1 million (Q4 2022), and $18.7 million (Q1 2022).